CA
NZ
UK
AU
IND
US
● GrossMarginwidened to 58.0% from 55.2%, with Adjusted EBITDA reaching a 23.4% margin.
● Net newBusinessawards climbed 28.2% to $795.7 million, lifting book-to-bill to 1.13x.
● NoEarningsrelease, financing, regulatory development, contract news, partnership, or management change was verified behind the decline.
● NoEarningsrelease, guidance revision, downgrade, partnership, regulatory development, or management change was tied to the session.
● KAPA shares closed at $0.870 on October 7, 2026, a loss of 24.35% that erased roughly a quarter of the stock's value.
● NXTS shares closed at $1.080 on October 7, 2026, a loss of 22.30% that erased roughly a fifth of the stock's value.
● NoEarningsreport, guidance change, regulatory development, reimbursement decision, financing, or analyst action has been verified as the driver.
● No clinical trial update, regulatory development,Earningsreport, financing, partnership, or analyst action has been verified as the driver.
● CRBU shares closed at $0.617 on October 7, 2026, a decline of 45.60% that nearly cut the company'sMarket Valuein half.
● CVM shares closed at $2.130 on October 7, 2026, a loss of 22.26% that erased roughly a fifth of the stock's value.
Please wait processing your request...